We noticed that serum MIC-1 had an outstanding performance for distinguishing CA19.9-negative pancreatic carcinomas from non–pancreatic carcinoma controls including benign pancreas tumors (AUROC, 0.886; 95% CI, 0.865–0.906; Figure 2b). Here, GDF15 is linked to exocrine pancreatic carcinoma.